Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 8, Pages 1922-1927
Publisher
Proceedings of the National Academy of Sciences
Online
2017-02-08
DOI
10.1073/pnas.1610197114
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms
- (2015) Fiona McPhee et al. ADVANCES IN THERAPY
- Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region
- (2015) Christoph Sarrazin et al. ANTIVIRAL RESEARCH
- Hepatitis C Treatment: The Data Flood Goes on—An Update From the Liver Meeting 2014
- (2015) Jean-Michel Pawlotsky GASTROENTEROLOGY
- Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: Table 1
- (2015) Fabien Zoulim et al. GUT
- Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection
- (2015) Sheng-Shun Yang et al. Hepatology International
- Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
- (2015) Andrew J. Muir et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
- (2015) Fred Poordad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- From non-A, non-B hepatitis to hepatitis C virus cure
- (2015) Jean-Michel Pawlotsky et al. JOURNAL OF HEPATOLOGY
- Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine
- (2015) Jacob Lalezari et al. JOURNAL OF HEPATOLOGY
- Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy
- (2015) Satoshi Yoshimi et al. JOURNAL OF MEDICAL VIROLOGY
- Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study
- (2015) Anita Kohli et al. LANCET
- Editorial Commentary: Barrier to Resistance: Lessons From 2 Direct-Acting Hepatitis C Virus Inhibitors, MK-5172 and Sofosbuvir
- (2014) X. Tong et al. CLINICAL INFECTIOUS DISEASES
- Simeprevir With Peginterferon and Ribavirin Leads to High Rates of SVR in Patients With HCV Genotype 1 Who Relapsed After Previous Therapy: A Phase 3 Trial
- (2014) Xavier Forns et al. GASTROENTEROLOGY
- Dysregulation of Retinoic Acid Receptor Diminishes Hepatocyte Permissiveness to Hepatitis B Virus Infection through Modulation of Sodium Taurocholate Cotransporting Polypeptide (NTCP) Expression
- (2014) Senko Tsukuda et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
- (2014) Ira M Jacobson et al. LANCET
- A mechanistic theory to explain the efficacy of antiretroviral therapy
- (2014) Sarah B. Laskey et al. NATURE REVIEWS MICROBIOLOGY
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Advances in and the future of treatments for hepatitis C
- (2014) Robert Cheng et al. Expert Review of Gastroenterology & Hepatology
- Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection
- (2013) Gregory T. Everson et al. GASTROENTEROLOGY
- On the History of Hepatitis C Virus Cell Culture Systems
- (2013) Volker Lohmann et al. JOURNAL OF MEDICINAL CHEMISTRY
- Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
- (2013) Troels K H Scheel et al. NATURE MEDICINE
- The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection
- (2013) Ralf Bartenschlager et al. NATURE REVIEWS MICROBIOLOGY
- Current and Future Therapies for Hepatitis C Virus Infection
- (2013) T. Jake Liang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
- (2013) J. Guedj et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pharmacokinetic/Pharmacodynamic Predictors of Clinical Potency for Hepatitis C Virus Nonnucleoside Polymerase and Protease Inhibitors
- (2012) Micaela B. Reddy et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
- (2012) Yoshiyuki Suzuki et al. JOURNAL OF HEPATOLOGY
- Antiretroviral dynamics determines HIV evolution and predicts therapy outcome
- (2012) Daniel I S Rosenbloom et al. NATURE MEDICINE
- A quantitative basis for antiretroviral therapy for HIV-1 infection
- (2012) Benjamin L Jilek et al. NATURE MEDICINE
- Dose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance
- (2011) M. E. S. Sampah et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Critical Subset Model Provides a Conceptual Basis for the High Antiviral Activity of Major HIV Drugs
- (2011) L. Shen et al. Science Translational Medicine
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
- (2010) L. Rong et al. Science Translational Medicine
- A novel method for determining the inhibitory potential of anti-HIV drugs
- (2009) Lin Shen et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
- (2008) Lin Shen et al. NATURE MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More